Prosecutors say evidence is 'strong' against suspects in New Mexico park shooting that killed 3
New York Times denounces Trump's 'intimidation tactics' against reporters
Some US embassies in Europe post warnings to would-be visa seekers: Watch your step
Australian government seeks to win back voters with household relief
Governor amends Virginia's budget bill to increase rainy-day reserves over changes in Washington
Massachusetts regulator subpoenas Robinhood over sports betting
Texas hires Xavier's Sean Miller, the coach who beat the Longhorns in the NCAA Tournament
Cam Ward shows off his arm at Miami pro day. Now Titans will decide if he's worth the No. 1 pick
(Reuters) - COVID-19 vaccine maker BioNTech's cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial, the German company said on Tuesday.
The trial met its primary endpoint, with data demonstrating a statistically significant improvement in the overall response rate in patients treated with the mRNA immunotherapy candidate BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab, compared to a historical control in patients with advanced melanoma, BioNTech said.
The biotech company said in March it was shifting its focus towards cancer drug development, as it adjusts to the decline in its COVID-19 vaccine business.
(Reporting by Isabel Demetz in Gdansk; Editing by Milla Nissi)
